InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,973.10
(
0.00%
)
US TECH 100
20,508.40
(
-0.16%
)
Dow Jones
43,729.34
(
0.00%
)
Brent Oil
74.52
(
-1.25%
)
Bitcoin
76,141.34
(
0.32%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Moanrch

Send PM Follow Ignore
Followers 0
Posts 213
Boards Moderated 0
Alias Born 10/24/2012

Moanrch

Re: investor maven post# 39517

Monday, 11/25/2013 12:16:40 AM

Monday, November 25, 2013 12:16:40 AM

Post# of 80490
If you read EMA http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/11/news_detail_001968.jsp&mid=WC0b01ac058004d5c1 there you can find:"In addition, in a recently discontinued phase III study that compared Iclusig with imatinib with a median treatment duration of 3 months, there was a higher number of occlusive vascular events reported in the Iclusig arm…" and it's take some times, probably 2 years to conduct new trial…
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up